Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Reliability of Expired Allergens in Patch Testing: A Comparative Study With Non-Expired Series

10 de agosto de 2026 actualizado por: Laurie Parsons, University of Calgary
Patch testing remains the gold standard in the diagnosis of allergic contact dermatitis. Patches used in testing consist of a wide spectrum of allergens, with variability in the stability of products over time. Due to limited allergen stability, careful storage and preparation is needed to prevent product degradation over time. Expiration dates are provided by manufacturers to ensure stability and reactivity, while minimizing the risk of product degradation contributing to inaccurate testing results. Preparation of patch series can be time intensive and procurement of allergens comes with an associated economic burden. Expired allergens are not routinely used in patch testing, however many clinics have expired allergens accessible. There is paucity of evidence comparing the reactivity of expired vs non-expired patch series. If expired allergens remain effective, this could result in significant cost-savings and accessibility implications for dermatology practice.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

In brief, review of the medical literature showed two comparable studies out of India and Spain suggesting that expired allergen series may be used beyond their labeled expiry dates, with some variability noted amongst duration of expiry, that the investigators will also aim to analyze.

Regarding allergen stability, there were also several studies focused on this domain. The European Society of Contact Dermatitis (ESCD) released guidelines in 2015, outlining optimal methods for allergen storage such as storage at 4 degrees celsius and strict protection from ultraviolet light exposure. While most allergens are dispersed in petrolatum (white soft paraffin), some substances are better tested in solutions such as water (aqueous) or ethanol. Several allergens with high vapour pressure require more frequent renewal and strict storage conditions such as fragrance chemicals, acrylates and isocyanates. Other substances such as glutaraldehyde in petrolatum (pet.) and formaldehyde in aqueous solution (aq.) are susceptible to instability and deterioration. An additional study assessed volatility over time of several select compounds and described high volatility in acrylates, glutaraldehyde, and fragrances, while describing partial volatility of formaldehyde and low volatility of nickel sulfate.

Study participants will include all eligible adults seen in patch testing clinic who maintain an indication for patch testing and consent to participation. The study will be utilizing 10 allergens from the North American Contact Dermatitis Group (NACDG) 80 Series for inclusion in the study.

The allergen selections are primarily based on compounds with a higher likelihood for volatility, in addition to inclusion of two comparator compounds with lower volatility. Expiration intervals include 1 year, 2 years, 3 years, and 4 years. The compounds selected are as follows, including their dispersion compound: nickel sulfate hexahydrate (5% pet.), cobalt (II) chloride hexahydrate (2.5% pet.), hydroperoxides of linalool (1% pet.), hydroperoxides of limonene (0.3% pet.), fragrance mix 1 (8.0% pet.), myroxylon pereirae resin (balsam of Peru) (25.0% pet.), methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) (0.02% aq.), formaldehyde (2.0% aq.), tixocortol-21-pivalate (1.0% pet.), and budesonide (0.1% pet.).

The patch testing results will be compared to corresponding non-expired allergens from the same manufacturer with the same preparation tested simultaneously. Both series will be placed simultaneously in differing locations on the participant's back, ensuring both are placed in sun protected areas with no underlying dermatitis.

Once in clinic, standard patch test series are applied on patch testing day, with the participant instructed not to shower or scratch the area throughout testing. At 48h, the patches are removed and photos are taken of the participant's back which are sent to the Dermatologist for virtual reading. At either 96h or 120h, the participant returns to the clinic for final reading. Both morphology and intensity of positives are graded on a standard patch test scale (irritant reaction), +/- for doubtful, + for erythema and infiltration, ++ for edematous or vesicular and +++ for spreading, bullous or ulcerative. Positive allergens scored + or greater are considered a true allergic contact allergen and assessed for relevance based on clinical context. The Dermatologist provides information sheets on all positive allergens, counsels on the relevance to their clinical history and allergen avoidance going forward, as well as providing the participant with a safe product list via the ACDS Contact Allergen Management Program (CAMP) database.

The investigators are aiming for enrolment of 100 participants which should theoretically provide the study with at least 5-10 participants testing positive to each of the four listed allergens with higher volatility and 20+ participants testing positive to the allergens with lower volatility. The investigators are aiming to assess concordance between expired and non-expired allergen reactions (positive vs negative), in addition to agreement in reaction intensity, differences in morphology, rates of false positives/negatives compared to control and concordance of irritant reaction between interventions.

The study will serve to lend valuable evidence as to whether expired allergens maintain clinical utility and could serve to reduce product waste, lower the economic burden and further improve accessibility of patch testing for use in resource limited settings.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

100

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • Alberta
      • Calgary, Alberta, Canadá, T2T 5C7
        • Richmond Road Diagnostic Treatment Centre
        • Contacto:
        • Investigador principal:
          • Laurie Parsons, Medical Doctor

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Adults (age 18 years or older) referred for patch testing.

Exclusion Criteria:

  • Relative or absolute contraindication to patch testing
  • Wide spread dermatitis prior to patch placement
  • Inability to return to clinic for reading of results
  • Patient non-consenting

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Otro: Enrolled Study Participants
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches. Therefore, there is no difference in intervention amongst study participants.
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches. Therefore, there is no difference in intervention amongst study participants.
All enrolled participants will be simultaneously patch tested with both expired and non-expired patches. Therefore, there is no difference in intervention amongst study participants.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Patch Testing Response (Positive/Negative) Concordance Rate (%) Between Non-Expired and Expired Allergens
Periodo de tiempo: Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.
Each allergen will be graded on response using a standard patch test scale including: irritant reaction ['IR'], '+/-' for doubtful, '+' for erythema and infiltration, '++' for edematous or vesicular and '+++' for spreading, bullous or ulcerative response that will be graded by the participating Dermatologist. Reactions graded '+', "++", or "+++" are consider a positive result. Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e. Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 92% of cases, the Nickel allergen in the non-expired and expired patches were both found to both be either positive or negative while in 8% of cases the response differed per the scale listed above.)
Standard patch test series are applied on Day 0. Participant removal of patches on Day 2 and self photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Reaction/Morphology Scoring Concordance (%)
Periodo de tiempo: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
For each positive allergen, severity (i.e. '+/-', '+', '++', "+++") and morphology (i.e. erythema, infiltration, edematous, vesicular, bullous, ulcerated) will be recorded. Concordance rate will be expressed as a percentage (%) between tested allergens that were non-expired and that were expired (i.e. Nickel sulfate hexahydrate was found to have a 92% concordance rate, meaning that in 70% of cases, the Nickel allergen in the non-expired and expired patches were both found to have the exact same severity and morphology, while in 30% of cases the severity and/or morphology differed per the scale listed above.)
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Stability Concordance (%) Amongst Mediums
Periodo de tiempo: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Each allergen is suspended within a medium, either petrolatum or aqueous solution. Not only will concordance (%) of positive and negative reactions be assessed amongst allergens and compared between non-expired and expired, but also between mediums to determine if there is a difference in stability over time amongst mediums used to determine if particular mediums result in degradation over time.
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Irritant Reaction Rates (%)
Periodo de tiempo: Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.
Final patch reading will score reactions on a standarized scale, with irritant reaction representing a negative reaction. However, we will compare rates and concordance (%) of irritant reactions between allergens to determine if their is reproducibility, or if expired allergens result in differing rates of irritant reactions. (i.e. Nickel sulfate allergen was shown to have a 50% increased rate of irritant reactions between the expired to non-expired allergens, meaning that Nickel resulted in an irritant reaction in 6 cases of the expired Nickel and 4 cases of the non-expired Nickel, suggesting that expired Nickel allergens may become more irritating over time, resulting in more irritant reactions.
Standard patch test series are applied on Day 0. Participant remove patches on Day 2, photos taken and sent to Dermatologist for virtual reading. Final reading completed in clinic by Dermatologist on Day 4 or 5, recording reaction scores, morphology.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Laurie Parsons, Medical Doctor, University Of Calgary

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de septiembre de 2026

Finalización primaria (Estimado)

1 de diciembre de 2027

Finalización del estudio (Estimado)

1 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

7 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de agosto de 2026

Publicado por primera vez (Actual)

14 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

14 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de agosto de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • REB26-0539

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Aside from eventual publication of study results to help guide practice, we will not be sharing granular study data with other researchers for expansion of the study.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .